Goodwill and Intangible Assets - Additional Information (Detail)	3 Months Ended	12 Months Ended
	Dec. 31, 2018 USD ($) Asset	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($) Asset	Dec. 31, 2017 USD ($)
Schedule Of Intangible Assets [Line Items]
Carrying value of assets	$ 38,872,537	$ 14,450,290	$ 38,872,537
Impairment charges		1,000,000	24,940,687
Goodwill impairment charges			$ 490,676
IPR&D [Member]
Schedule Of Intangible Assets [Line Items]
Number of assets | Asset	3		3
Intangible assets, amount	$ 13,418,967	12,418,967	$ 13,418,967	$ 38,245,871
Impairment charge	24,450,011	$ 1,000,000	24,450,011
IPR&D [Member] | Oncosyn Cancer Immunotherapy [Member]
Schedule Of Intangible Assets [Line Items]
Intangible assets, amount	$ 3,061,011		$ 3,061,011
IPR&D [Member] | HepTcell and SparVax-L [Member]
Schedule Of Intangible Assets [Line Items]
Number of assets | Asset	2		2
IPR&D [Member] | SparVax-L [Member]
Schedule Of Intangible Assets [Line Items]
Fair value of intangible assets	$ 1,000,000		$ 1,000,000
Carrying value of assets	22,389,000		$ 22,389,000
Impairment charge	$ 21,389,000
Minimum [Member] | IPR&D [Member]
Schedule Of Intangible Assets [Line Items]
Estimated Useful Lives		15 years
Maximum [Member] | IPR&D [Member]
Schedule Of Intangible Assets [Line Items]
Estimated Useful Lives		18 years
Maximum [Member] | IPR&D [Member] | HepTcell [Member]
Schedule Of Intangible Assets [Line Items]
Percent of fair value of reporting unit excess of carrying value	10.00%		10.00%
Research and Development [Member]
Schedule Of Intangible Assets [Line Items]
Amortization expense of intangible assets		$ 147,500	$ 83,652